Radiation Physics

PV QA 3 - Poster Viewing Q&A 3

TU_6_3174 - Establishing a Lu-177 Dotatate Therapy Program

Tuesday, October 23
1:00 PM - 2:30 PM
Location: Innovation Hub, Exhibit Hall 3

Establishing a Lu-177 Dotatate Therapy Program
W. Snyder1,2, K. Harpool1,2, J. W. Swanson1,2, P. Schantz1,2, A. Phan2, J. S. Dick1,2, and S. X. Cavanaugh2; 1Landauer Medical Physics, Glenwood, IL, 2Cancer Treatment Centers of America, Newnan, GA

Purpose/Objective(s): To establish a procedure and protocol for a new Lu-177 dotatate therapy program.

Materials/Methods: NCR 8.39 provides guidelines for releasing patients who have been administered a radioactive source. Since Lutetium 177 (Lu-177) is not listed, a calculation-based protocol is needed for compliance with NRC regulation. Equation 1 from NRC 8.39 was used to establish the release criteria. Patients are released with readings below 8 mrem/hr at 1 meter and also receive instructions prior to being released. Additional procedures for handling the radioactive byproduct were also implemented.

Results: To absorb radioactive contamination, the rooms, pumps, toilet, and restroom floor were covered with absorbent pads. The patient was given his/her own restroom, and instructions to flush 2-3 times each use. An amino acid infusion was given (containing L-lysine and L-arginine) for 30-45 minutes at a rate of 250 ml/hr. The flow rate of the lutetium dotatate began at 50 ml/hr, increased to 150 ml/hr, and then increased again up to 250 ml/hr, based on patient tolerance. The Lu-177 infusion took 45-60 minutes and the amino acids continued until the entire 1L bag was delivered. The total infusion time is 4-5 hours. The patient had no outside contact during the time of infusion. After infusion is complete, the patient is surveyed at 1 meter and is eligible for release to the public with a survey reading of less than 8 mrem/hr with special instructions. Lu-177m is a bi-product of the Lu-177 production, and decays with a half-life of 160 days. Therefore, excess lutetium and any soiled linens were stored in a separate shielded waste container and picked up by a nuclear waste disposal company. A total of 6 treatments have been treated to date. All had a 200 mCi prescription, and the amount of Lu-177 infused was from 191.67-199.9 (mean 195.8 mCi). Total times from all 6 treatments ranged from 4.08 hours to 6.42 hours (mean 5.4 hours). Final survey readings of patients at 1 m were from 1.7 mrem/hr to 3 mrem/hr (mean 2.43 mrem/hr).

Conclusion: These guidelines outline considerations necessary for implantation of a Lu-177 Dotatate therapy program.

Author Disclosure: W. Snyder: None. K. Harpool: None. J.W. Swanson: None. A. Phan: None. S.X. Cavanaugh: None.

Send Email for John Swanson


TU_6_3174 - Establishing a Lu-177 Dotatate Therapy Program

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Establishing a Lu-177 Dotatate Therapy Program